CoChat
Sign Up
Cited by 355

The DOI matches its Crossref record.

The Liposomal Formulation of Doxorubicin

Abraham, Sheela A., Waterhouse, Dawn N., Mayer, Lawrence D., Cullis, Pieter R., Madden, Thomas D., Bally, Marcel B.·2005·Methods in Enzymology
DOI 10.1016/s0076-6879(05)91004-5
Open this paper in CoChat — free account

Abstract

Doxorubicin is the best known and most widely used member of the anthracycline antibiotic group of anticancer agents. It was first introduced in the 1970s, and since that time has become one of the most commonly used drugs for the treatment of both hematological and solid tumors. The therapy-limiting toxicity for this drug is cardiomyopathy, which may lead to congestive heart failure and death. Approximately 2% of patients who have received a cumulative (lifetime) doxorubicin dose of 450-500 mg?m(2) will experience this condition. An approach to ameliorating doxorubicin-related toxicity is to use drug carriers, which engender a change in the pharmacological distribution of the drug, resulting in reduced drug levels in the heart. Examples of these carrier systems include lipid-based (liposome) formulations that effect a beneficial change in doxorubicin biodistribution, with two formulations approved for clinical use. Drug approval was based, in part, on data suggesting that beneficial changes in doxorubicin occurred in the absence of decreased therapeutic activity. Preclinical (animal) and clinical (human) studies showing that liposomes can preferentially accumulate in tumors have provided a rationale for improved activity. Liposomes represent ideal drug delivery systems, as the microvasculature in tumors is typically discontinuous, having pore sizes (100-780 nm) large enough for liposomes to move from the blood compartment into the extravascular space surrounding the tumor ce…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0076-6879(05)91004-5

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 42

  1. Abraham, 2002, Formation of transition metal-doxorubicin complexes inside liposomes, Biochim. Biphys. Acta, 1565, 41, 10.1016/S0005-2736(02)00507-2 · DOI
  2. Adlakha-Hutcheon, 1999, Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity, Nat. Biotechnol., 17, 775, 10.1038/11710 · DOI
  3. Allen, 2002, Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol), Biosci. Rep., 22, 225, 10.1023/A:1020186505848 · DOI
  4. Bally, 1990, Liposomes with entrapped doxorubicin exhibit extended blood residence times, Biochim. Biophys. Acta, 1023, 133, 10.1016/0005-2736(90)90018-J · DOI
  5. Bolotin, 1994, Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandsomes, J. Liposome Res., 4, 455, 10.3109/08982109409037057 · DOI
  6. Bouma, 1986, Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties, Pharm. Weekbl. Sci., 8, 109, 10.1007/BF02086146 · DOI
  7. Chaires, 1982, Self-association of daunomycin, Biochemistry, 21, 3927, 10.1021/bi00260a004 · DOI
  8. Cheung, 1998, Loading of doxorubicin into liposomes by forming Mn2+ drug complexes, Biochim. Biophys. Acta, 1414, 205, 10.1016/S0005-2736(98)00168-0 · DOI
  9. Cullis, 1989, Generating and loading of liposomal systems for drug-delivery applications, Adv. Drug Deliv. Rev., 3, 267, 10.1016/0169-409X(89)90024-0 · DOI
  10. Cullis, 1991, pH gradients and membrane transport in liposomal systems, Trends Biotechnol., 9, 268, 10.1016/0167-7799(91)90088-Y · DOI
  11. Fenske, 1998, Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients, Biochim. Biophys. Acta, 1414, 188, 10.1016/S0005-2736(98)00166-7 · DOI
  12. Fiallo, 1998, Circular dichroism studies on anthracycline antitumor compounds. Relationship between the molecular structure and the spectroscopic data, J. Pharm. Sci., 87, 967, 10.1021/js970436l · DOI
  13. Fiallo, 1999, How Fe3+ binds anthracycline antitumor compounds. The myth and the reality of a chemical sphinx, J. Inorg. Biochem., 75, 105, 10.1016/S0162-0134(99)00040-9 · DOI
  14. Fiske, 1925, The colorimetric determination of phosphorus, J. Biol. Chem., 2, 375, 10.1016/S0021-9258(18)84756-1 · DOI
  15. Gabizon, 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res., 54, 987
  16. Haran, 1993, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta, 1151, 201, 10.1016/0005-2736(93)90105-9 · DOI · Paper page
  17. Harrigan, 1992, Determination of transmembrane pH gradients and membrane potentials in liposomes, Biophys. J., 63, 1336, 10.1016/S0006-3495(92)81711-3 · DOI
  18. Hope, 1985, Production of large unilamellar vesicles by a rapid extension procedure: Characterization of size, trapped volume, and ability to maintain a membrane potential, Biochim. Biophys. Acta, 812, 55, 10.1016/0005-2736(85)90521-8 · DOI
  19. Hortobagyi, 1997, Anthracyclines in the treatment of cancer. An overview, Drugs, 54, 1
  20. Lasic, 1996, Doxorubicin in sterically stabilized liposomes, Nature, 380, 561, 10.1038/380561a0 · DOI
  21. Lasic, 1992, Gelation of liposome interior. A novel method for drug encapsulation, FEBS Lett., 312, 255, 10.1016/0014-5793(92)80947-F · DOI
  22. Li, 1998, Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient, Biochim. Biophys. Acta, 1415, 23, 10.1016/S0005-2736(98)00175-8 · DOI
  23. Madden, 1990, The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey, Chem. Phys. Lipids, 53, 37, 10.1016/0009-3084(90)90131-A · DOI
  24. Mayer, 1985, Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles, Biochim. Biophys. Acta, 817, 193, 10.1016/0005-2736(85)90084-7 · DOI
  25. Mayer, 1986, Techniques for encapsulating bioactive agents into liposomes, Chem. Phys. Lipids, 40, 333, 10.1016/0009-3084(86)90077-0 · DOI
  26. Mayer, 1989, Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice, Cancer Res., 49, 5922
  27. Mayer, 1994, The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin, J. Liposome Res., 4, 529, 10.3109/08982109409037060 · DOI
  28. Menozzi, 1984, Self-association of doxorubicin and related compounds in aqueous solution, J. Pharm. Sci., 73, 766, 10.1002/jps.2600730615 · DOI
  29. Needham, 2000, A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model, Cancer Res., 60, 1197
  30. Olson, 1979, Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes, Biochim. Biophys. Acta, 557, 9, 10.1016/0005-2736(79)90085-3 · DOI
  31. Papahadjopoulos, 1991, Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl. Acad. Sci. USA, 88, 11460, 10.1073/pnas.88.24.11460 · DOI
  32. Parr, 1993, The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade, Biochim. Biophys. Acta, 1168, 249, 10.1016/0005-2760(93)90132-S · DOI
  33. Pegram, 1999, Inhibitory effects of combinations of HER-2⧸neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, 18, 2241, 10.1038/sj.onc.1202526 · DOI
  34. Pegram, 2000, Trastuzumab and chemotherapeutics: Drug interactions and synergies, Semin. Oncol., 27, 21
  35. Redelmeier, 1989, Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients, Biophys. J., 56, 385, 10.1016/S0006-3495(89)82684-0 · DOI
  36. Szoka, 1978, Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation, Proc. Natl. Acad. Sci. USA, 75, 4194, 10.1073/pnas.75.9.4194 · DOI
  37. Szoka, 1980, Comparative properties and methods of preparation of lipid vesicles (liposomes), Annu. Rev. Biophys. Bioeng., 9, 467, 10.1146/annurev.bb.09.060180.002343 · DOI
  38. Waterhouse, 2001, A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles, Drug Safety, 24, 903, 10.2165/00002018-200124120-00004 · DOI
  39. Woodle, 1989, Liposome preparation and size characterization, Methods Enzymol., 171, 193, 10.1016/S0076-6879(89)71012-0 · DOI
  40. Forssen, 1979, In vitro and in vivo studies with adriamycin liposomes, Biochem. Biophys. Res. Commun., 91, 1295, 10.1016/0006-291X(79)91207-5 · DOI
  41. Hobbs, 1998, Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment, Proc. Natl. Acad. Sci. USA, 95, 4607, 10.1073/pnas.95.8.4607 · DOI · Paper page
  42. Rahman, 1980, Liposomal protection of adriamycin-induced cardiotoxicity in mice, Cancer Res., 40, 1532

Cited by

Sorted by citations

Metadata

Authors
Abraham, S. A., Waterhouse, D. N., Mayer, L. D., Cullis, P. R., Madden, T. D., & Bally, M. B.
Venue
Methods in Enzymology
Publisher
Elsevier
Published
2005
Pages
71-97
ISSN
0076-6879
DOI
10.1016/s0076-6879(05)91004-5
Cited by
355
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review